116 related articles for article (PubMed ID: 16770110)
21. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
[TBL] [Abstract][Full Text] [Related]
22. [Scleroderma-like skin sclerosis induced by docetaxel chemotherapy for hormone refractory prostate cancer: a case report].
Maehana T; Mizuno T; Muto M; Nishiyama N; Yanase M
Nihon Hinyokika Gakkai Zasshi; 2010 Sep; 101(6):726-9. PubMed ID: 20954379
[TBL] [Abstract][Full Text] [Related]
23. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
24. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
26. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
27. Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.
Hervonen P; Joensuu H; Joensuu T; Ginman C; McDermott R; Harmenberg U; Nyandoto P; Luukkaala T; Hemminki A; Zaitsev I; Heikkinen M; Nilsson S; Luukkaa M; Lehtinen I; Kellokumpu-Lehtinen PL
Anticancer Res; 2012 Mar; 32(3):953-6. PubMed ID: 22399616
[TBL] [Abstract][Full Text] [Related]
28. [A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone].
Ito H; Inamura S; Taga M; Tsuchiyama K; Kusukawa N; Oyama N; Akino H; Yokoyama O
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1245-7. PubMed ID: 24047790
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
Ide H; Kikuchi E; Kono H; Nagata H; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
Jpn J Clin Oncol; 2010 Jan; 40(1):79-84. PubMed ID: 19837689
[TBL] [Abstract][Full Text] [Related]
30. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
31. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H
Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473
[TBL] [Abstract][Full Text] [Related]
32. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Ladoire S; Eymard JC; Zanetta S; Mignot G; Martin E; Kermarrec I; Mourey E; Michel F; Cormier L; Ghiringhelli F
Anticancer Res; 2010 Oct; 30(10):4317-23. PubMed ID: 21036758
[TBL] [Abstract][Full Text] [Related]
33. [Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].
Batman E; de Wit R
Ned Tijdschr Geneeskd; 2005 Oct; 149(44):2442-5. PubMed ID: 16285357
[TBL] [Abstract][Full Text] [Related]
34. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.
Nelius T; Klatte T; de Riese W; Filleur S
Int Urol Nephrol; 2008; 40(1):97-104. PubMed ID: 17602304
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
36. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Bertelli G; Heouaine A; Arena G; Botto A; Garrone O; Colantonio I; Occelli M; Fea E; Giubergia S; Merlano M
Cancer Chemother Pharmacol; 2006 Jan; 57(1):46-51. PubMed ID: 16001175
[TBL] [Abstract][Full Text] [Related]
37. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; De Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
BJU Int; 2007 Oct; 100(4):775-9. PubMed ID: 17535276
[TBL] [Abstract][Full Text] [Related]
38. [Combination chemotherapy of docetaxel and UFT against hormone refractory prostate cancer].
Shimasaki T; Miyazawa K; Moriyama M; Tanaka T; Sato I; Nakaya N; Nakajima H; Kubo A; Suzuki K; Motoo Y
Hinyokika Kiyo; 2011 Mar; 57(3):163-6. PubMed ID: 21586891
[TBL] [Abstract][Full Text] [Related]
39. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
40. [AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression--PRINCE].
Rexer H
Urologe A; 2006 Jul; 45(7):872. PubMed ID: 16791626
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
